Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Netease (NTES) : A Zweig-type growth pick


Bookmark and Share

 John Reese assesses stocks based on the criteria of a select group of well-known investors with very strong track records of long-term success.

 In his Validea advisory, he looks at Chinese gaming stock, Netease (NASDAQ: NTES) based on the investment strategy of Martin Zweig, a long established growth investor. Here, he highlights some of the ways that this stock passes the "Zweig test."

"Netease operates an interactive online community in China, and is a provider of Chinese language content and services through its online games, Internet portal and wireless value-added services businesses.

"According to Zweig's investment strategy, the P/E of a company must be greater than 5 to eliminate weak companies, but not more than 3 times the current market P/E because the situation is much too risky, and never greater than 43.

Advertisement
Banner

"NTES's P/E is 17.33, based on trailing 12 month earnings, while the current market PE is 14.00. Therefore, it passes the first test.

"Revenue growth must not be substantially less than earnings growth. For earnings to continue to grow over time they must be supported by a comparable or better sales growth rate and not just by cost cutting or other non-sales measures.

"NTES's revenue growth is 33.79%, while it's earnings growth rate is 34.88%, based on the average of the 3, 4 and 5 year historical eps growth rates. Therefore, NTES passes this criterion.

"If the growth rate of the prior three quarter's earnings, 50.00%, (versus the same three quarters a year earlier) is less than the growth rate of the current quarter earnings, 100.00%, (versus the same quarter one year ago) then the stock passes.

"In addition, the EPS growth rate for the current quarter, 100.00% must be greater than or equal to the historical growth which is 34.88%. NTES would therefore pass this test.

"Companies must show persistent yearly earnings growth. To fulfill this requirement a company's earnings must increase each year for a five year period.

"NTES, whose annual EPS growth before extraordinary items for the previous 5 years (from the earliest to the most recent fiscal year) were 0.02, 0.04, 0.05, 0.06 and 0.07, passes this test.

"Another earnings test required is that the long-term earnings growth rate must be at least 15% per year. NTES's long-term growth rate of 34.88%, based on the average of the 3, 4 and 5 year historical eps growth rates, passes this test.

"In addition, a company must not have a high level of debt. A high level of total debt, due to high interest expenses, can have a very negative effect on earnings if business moderately turns down. 

"If a company does have a high level, an investor may want to avoid this stock altogether. NTES's Debt/Equity (0.00%) is not considered high relative to its industry (109.72%) and passes this test.

"The growth rate of the current quarter's earnings compared to the same quarter a year ago must also be positive. NTES's growth rate of 100.00% passes this test."


Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary